×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
Vision
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
Vision
Showcase
Demo
←
Home
/
Wiki
/
Event: MDS 2026 — Emerging Therapeutics in Parkinson's Disease
event
1,024 words
KG: therapeutics
2026-03-25
kind:event
section:events
state:published
mds2026
parkinsons
emerging-therapeutics
disease-modifying
gene-therapy
Contents
MDS 2026 — Emerging Therapeutics in Parkinson's Disease
Knowledge Graph
Related Hypotheses (30)
TREM2-Dependent Microglial Senescence Transition
Score: 0.74
SASP-Mediated Complement Cascade Amplification
Score: 0.73
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.70
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
CYP46A1 Overexpression Gene Therapy
Score: 0.66
APOE-Dependent Autophagy Restoration
Score: 0.63
Multi-Modal Stress Response Harmonization
Score: 0.60
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
Prefrontal sensory gating circuit restoration via PV interne
Score: 0.59
PARP1 Inhibition Therapy
Score: 0.58
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
Score: 0.57
Senescent Microglia Resolution via Maresins-Senolytics Combi
Score: 0.57
Synthetic Biology BBB Endothelial Cell Reprogramming
Score: 0.57
SASP-Mediated Cholinergic Synapse Disruption
Score: 0.56
Smartphone-Detected Motor Variability Correction
Score: 0.56
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Chromatin Accessibility Restoration via BRD4 Modulation
Score: 0.56
Blood-Brain Barrier SPM Shuttle System
Score: 0.56
Purinergic Signaling Polarization Control
Score: 0.55
Circadian Clock-Autophagy Synchronization
Score: 0.55
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.55
Senescent Cell Mitochondrial DNA Release
Score: 0.54
Retinal Vascular Microcirculation Rescue
Score: 0.54
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54
Circadian-Synchronized LRP1 Pathway Activation
Score: 0.53
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Phase-Separated Organelle Targeting
Score: 0.52
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
Membrane Cholesterol Gradient Modulators
Score: 0.52
Show 25 more
Related Analyses (30)
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Show 25 more
Related Experiments (30)
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40
Down Syndrome Alzheimer's Disease: Mechanisms and Therapeuti
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
GLP-1 Agonist Responder Prediction Study — Precision Medicin
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40
Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40
LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne
validation · proposed · Score: 0.40
Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper
clinical · proposed · Score: 0.40
Non-Motor Symptom Progression in Parkinson's Disease — Mecha
clinical · proposed · Score: 0.40
Parkinson's Disease Subtype Classification — Precision Medic
clinical · proposed · Score: 0.40
Peroxisome Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Prodromal Parkinson's Disease Biomarker Development — Early
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Sirtuin Pathway Dysfunction Validation in Parkinson's Diseas
clinical · proposed · Score: 0.40
Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40
Show 25 more
See Also (15)
VCP Proteostasis Modulation Therapy for ALS/FTD
idea · KG edge: references
CX3CR1 Modulation Therapy for Neurodegeneration
idea · KG edge: references
NLRP3 Inflammasome Hypothesis in Parkinson's Disease
hypothesis · KG edge: references
APOE contributes to Alzheimer's disease by regulating b
hypothesis · KG edge: references
SIRT6 Gene
gene · KG edge: references
PPARGC1A Gene
gene · KG edge: references
NURR1 Gene
gene · KG edge: references
C3 — Complement Component 3
gene · KG edge: references
BDNF Gene
gene · KG edge: references
TREM2 Protein (Triggering Receptor Expressed on Myeloid
entity · KG edge: references
TLR4 (Redirect)
redirect · KG edge: references
TFEB (Redirect)
redirect · KG edge: references
GFAP (Redirect)
redirect · KG edge: references
BACE1 (Redirect)
redirect · KG edge: references
Neuroinflammation PET Imaging in CBS/PSP
diagnostic · KG edge: inhibits
Show 10 more
Knowledge Graph (2 edges)
therapeutics
protects_against
age-related cognitive decline
therapeutics
inhibits
neuroinflammation